Ellen Miller Sonet, MBA, JD, chief strategy and policy officer, CancerCare, discusses the financial burden cancer patients face and how novel therapies and next-generation sequencing impact the burden.
Ellen Miller Sonet, MBA, JD, chief strategy and policy officer, CancerCare, discusses the financial burden patients with cancer face and how novel therapies and next-generation sequencing impact the burden.
Transcript
How big of an impact does financial burden have on patients with cancer?
A cancer diagnosis and its treatment has enormous financial consequences for patients. There is not only the costs associated with treatment, but there is also the ancillary, nonmedical costs, such as transportation, home healthcare, possible counseling, lodging, childcare. There’s also the lost income for the patient, and often for the caregiver.
Have targeted therapies and immunotherapies affected financial burdens, and will next-generation sequencing have an impact?
Immunotherapies, as exciting as they may be for patients, can also pose enormous financial challenges. Often, they’re inaccessible to patients because of costs and the insurance policies designation in formularies can make the unreachable for certain patients. It’s really unfortunate because these therapies can really make a difference in patients’ lives. But, if they’re inaccessible, then they can’t make that difference.
I think NGS can have an effect in helping determine which patients are most appropriate for targeted therapies, however the NGS also needs to be covered by insurance plans. And again, if insurers aren’t willing to make that part of their policy, then again, patients can’t access it.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More